Business Maverick

Business Maverick

Wegovy’s newly verified heart benefits under review by Medicare

Wegovy’s newly verified heart benefits under review by Medicare
Packets of Wegovy at the Novo Nordisk A/S production facilities in Hillerod, Denmark, on 12 June 2023. (Photo: Carsten Snejbjerg / Bloomberg via Getty Images)

The US federal health insurance, Medicare may soon be required to cover the blockbuster weight-loss drug Wegovy for heart disease patients with obesity after regulators approved an expanded label last week.

The Centers for Medicare and Medicaid Services “is reviewing the FDA’s action to expand use of Wegovy to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease and either obesity or overweight”, a spokesperson said in an email. The agency, known as CMS, will share additional information as appropriate, according to the spokesperson.

Medicare, the health insurance programme for the elderly and some people on long-term disability, doesn’t currently cover weight-loss drugs, which it puts in the same category as treatments for balding and erectile dysfunction. But after the US Food and Drug Administration said Wegovy could be used to help prevent life-threatening cardiovascular events, it raises the question of whether Medicare prescription drug programmes will now have to cover it for patients with a history of heart disease.

“Medicare will cover those drugs for the treatment of cardiovascular conditions among people with obesity” if the FDA were to expand the label, the Congressional Budget Office said in written responses to questions released last week following a hearing in late January. 

The CBO, which analyzes the economic impacts of proposed legislation, also said it was refining its projection of what other conditions are likely to be covered by Medicare and will share more information when available. 

“Regarding Medicaid coverage, states would be required to cover Wegovy for the purposes to prevent cardiovascular disease in people with obesity,” CMS said. About a third of state Medicaid programmes currently cover Wegovy, sold by Novo Nordisk A/S, and other GLP-1 drugs for weight loss.


Comments - Please in order to comment.

Please peer review 3 community comments before your comment can be posted


This article is free to read.

Sign up for free or sign in to continue reading.

Unlike our competitors, we don’t force you to pay to read the news but we do need your email address to make your experience better.

Nearly there! Create a password to finish signing up with us:

Please enter your password or get a sign in link if you’ve forgotten

Open Sesame! Thanks for signing up.

We would like our readers to start paying for Daily Maverick...

…but we are not going to force you to. Over 10 million users come to us each month for the news. We have not put it behind a paywall because the truth should not be a luxury.

Instead we ask our readers who can afford to contribute, even a small amount each month, to do so.

If you appreciate it and want to see us keep going then please consider contributing whatever you can.

Support Daily Maverick→
Payment options